TrialNature communications2026

Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study.

Mo Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.